Therapeutic Angiogenesis Using Autologous CD34-Positive Cells for Vascular Diseases

Fujita, Yasuyuki; Kawamoto, Atsuhiko

doi:10.3400/avd.ra.22-00086

Cited by 4 publications

(3 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were divided into three groups according to the tertiles of CD34+ cell levels (Tertile 1, <0.51/µL; Tertile 2, 0.51-0.96/µL; and Tertile 3, >0.96/µL). The differences in the median of the day of a baseline CD34+ cell measurement were insignificant among these groups (median (IQR) 2 (3-5), 2 (3-5), and 2 (3)(4)(5) in Tertiles 1, 2, and 3, respectively; p = 0.63) (Supplemental Figure I).…”

Section: Resultsmentioning

confidence: 97%

“…EPCs contribute to form new vessels and repair endothelial injury by proliferating and differentiating into endothelial cells. 3,10 EPCs, in addition to neovascularization, induce neurogenesis via various cytokines and growth factors in the cerebral infarct areas. 11 In an in vivo study, intravenous CD34+ cell infusion after stroke promoted neurogenesis via neovascularization in mice.…”

Section: Discussionmentioning

confidence: 99%

“…EPCs play a pivotal role in neovascularization and endothelial repair after ischemia, which in turn can provide an optimal environment of tissue regeneration. 3 Hence, EPCs may act as a prognostic marker in patients with ischemia-related diseases.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association of circulating CD34+ cells level and prognosis after ischemic stroke

Mizuno,

Hoshino,

Ishizuka

et al. 2023

International Journal of Stroke

View full text Add to dashboard Cite

Background: CD34 is a transmembrane phosphoglycoprotein and a marker of hematopoietic and nonhematopoietic stem/progenitor cells. In experimental studies, CD34+ cells are rich sources of endothelial progenitor cells and can promote neovascularization and endothelial repair. The potential role of CD34+ cells in stroke patients remains unclear. Aims: We aimed to assess the prognostic effect of circulating CD34+ cell levels on the risk of vascular events and functional prognosis in stroke patients. Patients and Methods: In this prospective observational study, patients with ischemic stroke were consecutively enrolled within 1 week of onset and followed up for 1 year. Patients were divided into three groups according to tertiles of the level of circulating CD34+ cells (tertile 1, <0.51 /µL; tertile 2, 0.51–0.96 /µL; and tertile 3, >0.96 /µL). The primary outcome was a composite of major adverse cardiovascular events (MACEs), including nonfatal stroke, nonfatal acute coronary syndrome, and vascular death. The secondary outcomes included the modified Rankin scale (mRS) scores. Results: A total of 524 patients (mean age, 71.3 years; male, 60.1%) were included. High CD34+ cell levels were associated with younger age (p<0.001) and low National Institutes of Health Stroke Scale scores at admission (p=0.010). No significant differences were found in the risk of MACEs among the three groups (annual rates: 15.0%, 13.4%, and 12.6% in tertiles 1, 2, and 3, respectively; log-rank p=0.70). However, there were significant differences in the mRS scores at 3 months (median [interquartile range]; 2 [1–4], 1 [1–3], and 1 [0–2] in tertiles 1, 2, and 3, respectively; p=0.010) and 1 year (3 [1–4], 2 [1–4], and 1 [0–3]; p<0.001) among these groups. After multivariable adjustments, a higher CD34+ cell level was independently associated with good functional outcomes (mRS score of 0–2) at 3 months (adjusted odds ratio [OR], 1.43; 95% confidence interval [CI], 1.01–2.05) and 1 year (adjusted OR, 1.53; 95% CI, 1.09–2.16). Conclusions: Although no correlations were found between circulating CD34+ cell levels and vascular event risk, elevated CD34+ cell levels were associated with favorable functional recovery in stroke patients.

show abstract

Section: Resultsmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of circulating CD34+ cells level and prognosis after ischemic stroke

Mizuno,

Hoshino,

Ishizuka

et al. 2023

International Journal of Stroke

View full text Add to dashboard Cite

show abstract

Acute promyelocytic leukemia: the first reported case diagnosed by immunophenotyping in Mozambique

Mongo,

Matola,

Sigaúque

et al. 2024

Discov Med

View full text Add to dashboard Cite

Patients with acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), often present with severe leucocytosis and thrombocytopenia, which may lead to symptoms that require prompt diagnosis and treatment. Immunophenotyping combined with cytomorphology is a valuable tool for identifying APL patients. We describe the case of a 9-year-old male patient who was diagnosed with APL in July 2022 using immunophenotyping combined with cytomorphology. The patient was treated with chemotherapy and is now in full remission in the maintenance phase. This case demonstrated the importance of timely differential diagnosis using the correct tools, allowing inclusion in the appropriate treatment protocol.

show abstract

Myxolipoma in the buccal region: A case report and review of literature

Baba,

Fukui

et al. 2024

Journal of Oral and Maxillofacial Surgery, Medicine, and Pathol

View full text Add to dashboard Cite

Therapeutic Angiogenesis Using Autologous CD34-Positive Cells for Vascular Diseases

Cited by 4 publications

References 67 publications

Association of circulating CD34+ cells level and prognosis after ischemic stroke

Association of circulating CD34+ cells level and prognosis after ischemic stroke

Acute promyelocytic leukemia: the first reported case diagnosed by immunophenotyping in Mozambique

Myxolipoma in the buccal region: A case report and review of literature

Contact Info

Product

Resources

About